Common Equity: The sum of all common equity items.
Halozyme Therapeutics, Inc. (HALO) had Common Equity of $-55.24M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$492.97M |
|
$247.05M |
|
$82.47M |
|
$410.50M |
|
$198.00M |
|
$294.97M |
|
$-4.34M |
|
$290.63M |
|
$290.63M |
|
$247.05M |
|
$247.05M |
|
$247.05M |
|
$247.05M |
|
$294.97M |
|
$330.84M |
|
113.80M |
|
122.61M |
|
$2.17 |
|
$2.01 |
|
| Balance Sheet Financials | |
$1.85B |
|
$82.29M |
|
$1.63B |
|
$3.47B |
|
$476.09M |
|
$2.94B |
|
$3.05B |
|
$3.53B |
|
|
Common Equity |
$-55.24M |
$-1.53B |
|
$-55.24M |
|
113.94M |
|
| Cash Flow Statement Financials | |
$679.24M |
|
$-44.59M |
|
$259.78M |
|
$136.42M |
|
$1.03B |
|
$894.43M |
|
$51.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.88 |
|
-- |
|
-- |
|
1.02 |
|
-58.84 |
|
83.27% |
|
59.83% |
|
59.83% |
|
-- |
|
58.95% |
|
50.11% |
|
$668.27M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
0.62 |
|
0.94 |
|
95.95 |
|
-447.24% |
|
-16.15% |
|
7.11% |
|
8.55% |
|
$-0.48 |
|
$5.45 |
|
$5.54 |
|